The Russian Direct Investment Fund (RDIF), an investor of the Russian Covid-19 vaccine Sputnik V, announced on Sunday that the vaccine demonstrated a higher or equal tolerability profile among the 60 plus age group in San Marino during the inoculation campaign in the country. “Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. This preliminary analysis suggests a higher or equal tolerability profile of the Sputnik V vaccine in the 60+ age group, after both doses, as compared with other widely adopted Covid-19 vaccines,” said the statement. Nearly all reported AEFIs were mild or moderate and/or lasted less than 2 days,” the statement added. Sputnik V was the third vaccine to be granted an emergency use authorisation in India on April 12, 2021 after indigenously developed Covaxin and Covishield.

Source: Hindustan Times July 11, 2021 19:30 UTC